Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 ...

Jefferies analyst Akash Tewari maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on February 3 and set a price target of ...

A couple of months ago, healthcare equity research analyst Jared Holz from Mizuho spoke about Viking potentially being an acquisition target. During his discussion, Holz suggested that Viking could ...

He also sardonically targeted co-host David Faber and said “Look I’m sure that when they discovered the cotton gin, and ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

We recently published a list of Jim Cramer’s Thoughts on These 7 Stocks. In this article, we are going to take a look at ...

Real-time index price for TSX Diversified Banks EW Index (TXDE), along with buy or sell indicators, analysis, charts, ...

An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.

Eli Lilly is experiencing explosive growth thanks ... and the company's momentum in the GLP-1 realm seems to be the only thing Wall Street analysts are talking about these days.

Eli Lilly is set to report fourth-quarter earnings ... looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE ... in the GLP-1 realm seems to be the only thing Wall Street analysts are talking about these days.

The upcoming report from Eli Lilly (LLY) is expected to reveal quarterly earnings of $5.15 per share, indicating an increase of 106.8% compared to the year-ago period. Analysts forecast revenues of ...